Immunotherapy in Melanoma Articles | Page 3

Pembrolizumab Demonstrates Long-Term OS Benefit in Advanced Melanoma
Pembrolizumab (Keytruda) provides a long-term survival benefit in both ipilimumab-naïve and ipilimumab-treated patients with advanced melanoma.
Adjuvant Nivolumab Improves RFS Versus Ipilimumab in Melanoma
Adjuvant nivolumab (Opdivo) extended recurrence-free survival compared with adjuvant ipilimumab (Yervoy) in patients with advanced melanoma enrolled in the phase III CheckMate-238 trial.
Expert Discusses IDO/PD-1 and Other Emerging Combos in Melanoma
Adil Daud, MD, discusses combination regimens and biomarkers being explored to advance immunotherapy in the field of melanoma.
Weighing Efficacy and Tolerability for Adjuvant Ipilimumab in Advanced Melanoma
Treatment with ipilimumab has been shown to improve overall survival; however, this efficacy often comes with toxicity.
Adjuvant PD-1 Inhibition on Horizon in Melanoma
Several clinical trials are examining the use of adjuvant PD-1 inhibition for patients with melanoma, with a potential new standard of care on the horizon for those at high risk of recurrence following resection.
Weber Says Pembrolizumab/Epacadostat Could Become Frontline Treatment of Choice in Melanoma
Jeffrey S. Weber, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of brain metastases, the tolerability of the combination of ipilimumab and talimogene laherparepvec (Imlygic; T-VEC), and what is next on the horizon for pembrolizumab (Keytruda).
Expert Discusses Adjuvant Ipilimumab Regimens in Melanoma
Jean Jacques Grob, MD, PhD, discusses the efficacy and tolerability of different doses of ipilimumab given in the adjuvant setting for patients with melanoma.
Epacadostat/ Nivolumab Shows Promising Efficacy for Melanoma, Head and Neck Cancer
The combination of the IDO inhibitor epacadostat and nivolumab demonstrated promising signs of activity for patients with squamous cell carcinoma of the head and neck and those with melanoma.
Nivolumab/Ipilimumab Highly Active in Patients With Melanoma Brain Metastases
Nivolumab plus ipilimumab demonstrated an intracranial response rate of 42% in asymptomatic patients with melanoma brain metastases who had not received prior local therapy to the brain.
Publication Bottom Border
Border Publication